Slowing of the polyomavirus DNA replication fork in response to DDR

DDR 导致多瘤病毒 DNA 复制叉减慢

基本信息

  • 批准号:
    10289169
  • 负责人:
  • 金额:
    $ 23.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-24 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

Some DNA viruses utilize cellular DNA damage response (DDR) pathways to aid in viral DNA replication (e.g. HSV and HPV), while others may attenuate the DDR response (e.g. adenovirus), or even be subject to DNA replication arrest by DDR (e.g. EBV and polyomavirus (PyV)). PyV DNA replication has been an important simplified model of host cell DNA replication that utilizes a single viral protein (LT) for origin recognition and helicase function, and otherwise recruits cellular DNA replication proteins to replicate its viral genomes. The primary critical interactions required for PyV DNA replication are the three interactions between LT and the cellular single-strand DNA binding complex (RPA) and DNA polymerase alpha- primase (Polprim), all three interactions are required for synthesis to be initiated. We have identified conditions both in living cells and in vitro where DDR prevents viral DNA replication, and shown that this is mediated by ATR, and correlates with phosphorylation of each of these three proteins, specifically: LT, the second subunit of RPA, and the second subunit of Polprim. Preliminary studies shown herein demonstrate that the phosphorylation of LT (evaluated by creating phosphomimetic mutations) doesn’t affect most functions of LT (DNA binding, hexamerization, ATPase, binding to RPA and Polprim, stimulation of polymerization by Polprim), but it does dramatically inhibit DNA helicase progression. Synthesis of primers is deficient in a second pathway independent of this DDR effect on LT. Naïve LT and Polprim with RPA purified from DDR-activated cells is severely inhibited for primer synthesis, suggesting that at the replication fork there is a coordinated inhibition of both leading and lagging strand synthesis, through helicase and priming suppression, respectively. The two Aims of this proposal are to prepare phosphomimetic mutations of both the RPA and Polprim complexes at their DDR sites, and evaluate the function of these two complexes as we have done with the phosphomimetic LT. Their functions alone, as well as in conjunction with both wt and phosphomimetic mutations of both of the other complexes will elucidate the detailed mechanisms behind how replication fork progression can be inhibited in a coordinated fashion in response to DDR. This has ramifications on how DNA replication stress can be targeted for cancer treatment and for treatment of human PyV infections.
一些DNA病毒利用细胞DNA损伤反应(DDR)途径来帮助病毒DNA复制(例如HSV和HPV),而其他DNA病毒可以减弱DDR反应(例如腺病毒),或者甚至受到DDR的DNA复制阻滞(例如EBV和多瘤病毒(PyV))。PyV DNA复制是宿主细胞DNA复制的重要简化模型,其利用单个病毒蛋白(LT)进行起点识别和解旋酶功能,并且以其他方式招募细胞DNA复制蛋白来复制其病毒基因组。PyV DNA复制所需的主要关键相互作用是LT与细胞单链DNA结合复合物(RPA)和DNA聚合酶α-引发酶(Polymerase)之间的三种相互作用,所有三种相互作用都是启动合成所需的。我们已经在活细胞和体外鉴定了DDR阻止病毒DNA复制的条件,并表明这是由ATR介导的,并与这三种蛋白质中的每一种的磷酸化相关,具体地说:LT,RPA的第二亚基和Pollycoprotein的第二亚基。本文所示的初步研究表明,LT的磷酸化(通过产生磷酸化模拟突变来评估)不影响LT的大多数功能(DNA结合、六聚化、ATP酶、与RPA和Polypeptide的结合、Polypeptide对聚合的刺激),但它确实显著抑制DNA解旋酶的进展。引物的合成是缺乏在第二个途径独立的这种DDR对LT的影响。幼稚LT和Polymorphism与RPA纯化从DDR激活的细胞被严重抑制引物合成,这表明在复制叉有一个协调的抑制前导和滞后链的合成,通过解旋酶和引发抑制,分别。该建议的两个目的是在RPA和Polypeptide复合物的DDR位点制备磷酸化模拟突变,并评估这两种复合物的功能,就像我们对磷酸化模拟LT所做的那样。以及结合两种其它复合物的野生型和拟磷酸化突变,将阐明在一种复合物中如何抑制复制叉进展的详细机制。以协调一致的方式应对复员方案。这对DNA复制应激如何靶向癌症治疗和治疗人类PyV感染具有影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS MELENDY其他文献

THOMAS MELENDY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS MELENDY', 18)}}的其他基金

Creation and Validation of cell-based screening systems for SARS-CoV-2 drug targets
SARS-CoV-2 药物靶标细胞筛选系统的创建和验证
  • 批准号:
    10373681
  • 财政年份:
    2022
  • 资助金额:
    $ 23.93万
  • 项目类别:
Creation and Validation of cell-based screening systems for SARS-CoV-2 drug targets
SARS-CoV-2 药物靶标细胞筛选系统的创建和验证
  • 批准号:
    10618835
  • 财政年份:
    2022
  • 资助金额:
    $ 23.93万
  • 项目类别:
Slowing of the polyomavirus DNA replication fork in response to DDR
DDR 导致多瘤病毒 DNA 复制叉减慢
  • 批准号:
    10408848
  • 财政年份:
    2021
  • 资助金额:
    $ 23.93万
  • 项目类别:
Evaluation and development of E1-TopoI as a target for anti-HPV therapeutics
E1-TopoI 作为抗 HPV 治疗靶点的评估和开发
  • 批准号:
    8297142
  • 财政年份:
    2012
  • 资助金额:
    $ 23.93万
  • 项目类别:
Evaluation and development of E1-TopoI as a target for anti-HPV therapeutics
E1-TopoI 作为抗 HPV 治疗靶点的评估和开发
  • 批准号:
    8450078
  • 财政年份:
    2012
  • 资助金额:
    $ 23.93万
  • 项目类别:
Evaluation and development of E1-TopoI as a target for anti-HPV therapeutics
E1-TopoI 作为抗 HPV 治疗靶点的评估和开发
  • 批准号:
    8638888
  • 财政年份:
    2012
  • 资助金额:
    $ 23.93万
  • 项目类别:
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS
DNA 损伤触发 S 相检查点的机制
  • 批准号:
    6833488
  • 财政年份:
    2001
  • 资助金额:
    $ 23.93万
  • 项目类别:
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS
DNA 损伤触发 S 相检查点的机制
  • 批准号:
    6626784
  • 财政年份:
    2001
  • 资助金额:
    $ 23.93万
  • 项目类别:
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS
DNA 损伤触发 S 相检查点的机制
  • 批准号:
    6229425
  • 财政年份:
    2001
  • 资助金额:
    $ 23.93万
  • 项目类别:
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS
DNA 损伤触发 S 相检查点的机制
  • 批准号:
    7050337
  • 财政年份:
    2001
  • 资助金额:
    $ 23.93万
  • 项目类别:

相似海外基金

Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
  • 批准号:
    EP/Y000331/1
  • 财政年份:
    2023
  • 资助金额:
    $ 23.93万
  • 项目类别:
    Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
  • 批准号:
    10677295
  • 财政年份:
    2023
  • 资助金额:
    $ 23.93万
  • 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
  • 批准号:
    10635599
  • 财政年份:
    2023
  • 资助金额:
    $ 23.93万
  • 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
  • 批准号:
    10752320
  • 财政年份:
    2023
  • 资助金额:
    $ 23.93万
  • 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
  • 批准号:
    478927
  • 财政年份:
    2023
  • 资助金额:
    $ 23.93万
  • 项目类别:
    Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
  • 批准号:
    10855703
  • 财政年份:
    2023
  • 资助金额:
    $ 23.93万
  • 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
  • 批准号:
    10654210
  • 财政年份:
    2023
  • 资助金额:
    $ 23.93万
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    $ 23.93万
  • 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
  • 批准号:
    10667952
  • 财政年份:
    2023
  • 资助金额:
    $ 23.93万
  • 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
  • 批准号:
    10726986
  • 财政年份:
    2023
  • 资助金额:
    $ 23.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了